http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10016515-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcf5f8862c47d9c32ad47dc452711592 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15b8e76025fd9e54872fa57cf9b87758 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N2005-1094 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate | 2016-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86a1e9427c5c5b4fa4f5b224cd355533 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6edd9593943ea8ed841dda35434f162 |
| publicationDate | 2018-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-10016515-B2 |
| titleOfInvention | DMA, a bis-benzimidazole, confers radioprotection to the intestine via Akt/NFκB dual pathway activation |
| abstract | The present invention relates to dual activation of Akt/NFκB pathway by DMA (5-(4-methylpiperazin-1-yl)-2-[2′-(3,4-dimethoxyphenyl)-5′-benzimidazolyl]benzimidazole) to render radioprotection both in mammalian cells and in Balb/c mice. Further it selectively protects normal cells overs tumor tissues against lethal total body irradiation (TBI) and there was no activation of Akt/NFκB pathway by DMA in response to radiation in tumor tissues. A single dose of DMA before TBI protect mice from GI and HP acute radiation syndrome (ARS) and offered radioprotection through oral, i.v., i.p., and s.c route of administration. The half life of DMA in plasma is 3.5 h at oral dose and 90% clearance was observed in 16 h. DMA accumulates in high concentration in intestine, liver, kidney and spleen tissues, justifying the observed radioprotection to normal tissue even at single dose. This data provide molecular rationale that DMA is selective radioprotector to normal tissue and has the potential to improve clinical outcome of radiotherapy, valuable as adjuvants in cancer therapy and management of radiation emergencies. |
| priorityDate | 2016-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 380.